Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Craig Allred

Showing results (51-60 of 92) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancerXiao-Jun Ma, Susan G Hilsenbeck, Wilson Wang, et al.
Cancer|July 13, 2002
Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinomaJianzhou Wang, Thomas A Buchholz, Lavinia P Middleton, et al.
The Breast Journal|May 20, 2003
A roundtable discussion of aromatase inhibitors as therapy for breast cancerD Craig Allred, Michael Baum, Aman U Buzdar, et al.
Breast Cancer Research and Treatment|November 20, 2009
Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancerIlenia Migliaccio, Meng-Fen Wu, Carolina Gutierrez, et al.
Breast Cancer Research and Treatment|June 20, 2016
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patientsSasagu Kurozumi, Mary Padilla, Masafumi Kurosumi, et al.
Journal of the National Cancer Institute|March 6, 2003
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancerC Kent Osborne, Valerie Bardou, Torsten A Hopp, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 24, 2004
Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation studySyed K Mohsin, Heidi Weiss, Thomas Havighurst, et al.
Archives of Pathology & Laboratory Medicine|June 3, 2006
Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinomaKelly J Butnor, Andrew G Nicholson, D Craig Allred, et al.
Lancet (London, England)|August 9, 2003
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancerJenny C Chang, Eric C Wooten, Anna Tsimelzon, et al.
Clinical Breast Cancer|January 13, 2004
Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary resultsAndrea E Van Pelt, Syed Mohsin, Richard M Elledge, et al.
Pageof 10

Showing results (51-60 of 92) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2006
The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancerXiao-Jun Ma, Susan G Hilsenbeck, Wilson Wang, et al.
Cancer|July 13, 2002
Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinomaJianzhou Wang, Thomas A Buchholz, Lavinia P Middleton, et al.
The Breast Journal|May 20, 2003
A roundtable discussion of aromatase inhibitors as therapy for breast cancerD Craig Allred, Michael Baum, Aman U Buzdar, et al.
Breast Cancer Research and Treatment|November 20, 2009
Nuclear IRS-1 predicts tamoxifen response in patients with early breast cancerIlenia Migliaccio, Meng-Fen Wu, Carolina Gutierrez, et al.
Breast Cancer Research and Treatment|June 20, 2016
HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patientsSasagu Kurozumi, Mary Padilla, Masafumi Kurosumi, et al.
Journal of the National Cancer Institute|March 6, 2003
Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancerC Kent Osborne, Valerie Bardou, Torsten A Hopp, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 24, 2004
Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer: a validation studySyed K Mohsin, Heidi Weiss, Thomas Havighurst, et al.
Archives of Pathology & Laboratory Medicine|June 3, 2006
Expression of renal cell carcinoma-associated markers erythropoietin, CD10, and renal cell carcinoma marker in diffuse malignant mesothelioma and metastatic renal cell carcinomaKelly J Butnor, Andrew G Nicholson, D Craig Allred, et al.
Lancet (London, England)|August 9, 2003
Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancerJenny C Chang, Eric C Wooten, Anna Tsimelzon, et al.
Clinical Breast Cancer|January 13, 2004
Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary resultsAndrea E Van Pelt, Syed Mohsin, Richard M Elledge, et al.
Pageof 10